Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics

Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T... Pegylated interferon α (PEG IFN‐α) improves sustained virological response rates in chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action has been defined. This prospective study assessed the efficacy of PEG IFN‐α treatment in acute hepatitis C in relation to the kinetics of hepatitis C virus (HCV)‐specific CD4+ T cell responses during therapy and follow‐up. Forty subjects with proven acute hepatitis C who received either PEG IFN‐α plus ribavirin (n = 20) or PEG IFN‐α monotherapy (n = 20) for 24 weeks in addition to 14 untreated subjects with acute hepatitis C were prospectively followed. Serum HCV RNA, HCV‐specific CD4+ T cell responses, and cytokine production were measured before and during therapy and at follow‐up and correlated to the outcome. The sustained virological response rate was 85% with PEG IFN‐α/ribavirin combination and 80% with PEG IFN‐α monotherapy. Five untreated subjects had spontaneous recovery. The frequency, magnitude, and breadth of HCV‐specific CD4+ T helper 1 responses were significantly higher in treated subjects compared with untreated subjects with self‐limited disease or subjects with chronic evolution. The CD4+ T cell responses were maintained in subjects with sustained virological responses and self‐limited disease but fluctuated in those who developed chronic infection. In conclusion, PEG IFN‐α therapy in acute hepatitis induces high rates of sustained virological response and prevents choronicity, probably through efficient early stimulation of multispecific HCV‐specific CD4+ T helper 1 responses. (HEPATOLOGY 2004;39:1721–1731.) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hepatology Wiley

Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics

Loading next page...
 
/lp/wiley/pegylated-interferon-therapy-in-acute-hepatitis-c-relation-to-CkvXch0bQB
Publisher
Wiley
Copyright
Copyright © 2004 American Association for the Study of Liver Diseases
ISSN
0270-9139
eISSN
1527-3350
D.O.I.
10.1002/hep.20266
Publisher site
See Article on Publisher Site

Abstract

Pegylated interferon α (PEG IFN‐α) improves sustained virological response rates in chronic hepatitis C, but neither its role in acute hepatitis C nor the biologic basis for its action has been defined. This prospective study assessed the efficacy of PEG IFN‐α treatment in acute hepatitis C in relation to the kinetics of hepatitis C virus (HCV)‐specific CD4+ T cell responses during therapy and follow‐up. Forty subjects with proven acute hepatitis C who received either PEG IFN‐α plus ribavirin (n = 20) or PEG IFN‐α monotherapy (n = 20) for 24 weeks in addition to 14 untreated subjects with acute hepatitis C were prospectively followed. Serum HCV RNA, HCV‐specific CD4+ T cell responses, and cytokine production were measured before and during therapy and at follow‐up and correlated to the outcome. The sustained virological response rate was 85% with PEG IFN‐α/ribavirin combination and 80% with PEG IFN‐α monotherapy. Five untreated subjects had spontaneous recovery. The frequency, magnitude, and breadth of HCV‐specific CD4+ T helper 1 responses were significantly higher in treated subjects compared with untreated subjects with self‐limited disease or subjects with chronic evolution. The CD4+ T cell responses were maintained in subjects with sustained virological responses and self‐limited disease but fluctuated in those who developed chronic infection. In conclusion, PEG IFN‐α therapy in acute hepatitis induces high rates of sustained virological response and prevents choronicity, probably through efficient early stimulation of multispecific HCV‐specific CD4+ T helper 1 responses. (HEPATOLOGY 2004;39:1721–1731.)

Journal

HepatologyWiley

Published: Jun 1, 2004

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off